Clinical Report: Erratum on Follicular Dendritic Cell Sarcoma and IgG4-RD
Background
Follicular dendritic cell sarcoma (FDCS) is a rare malignant neoplasm that can occur in lymphatic nodes and extranodal sites. Its association with IgG4-related disease (IgG4-RD) is noted in the literature, which may lead to misdiagnosis and complicate treatment. Understanding the characteristics of FDCS in the context of IgG4-RD is essential for accurate diagnosis and management.
Data Highlights
No numerical or trial data is presented in the erratum.
Key Findings
Correction of reference numbers in Table 1 of the original article.
FDCS can present with increased IgG4-positive plasma cells, as noted in the literature.
IgG4-RD is a systemic immune-mediated condition that can complicate the diagnosis of FDCS.
Some FDCS lesions may fulfill histologic criteria for IgG4-RD.
Complete surgical excision is the standard therapy for localized FDCS.
Clinical Implications
Clinicians should be aware of potential reference errors in published literature and ensure accurate interpretation of clinical data. The association between FDCS and IgG4-RD requires careful evaluation to avoid misdiagnosis.
Conclusion
The erratum emphasizes the importance of accuracy in clinical reporting and the need for vigilance in interpreting complex cases involving FDCS and IgG4-RD.
Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD discuss results from the Pumitamig + DB-1305/BNT325 trial, which were presented at the 2026 ESMO Breast Cancer Congress.
